Semaglutide 20mg Research Peptide
Semaglutide is a long-acting GLP-1 receptor agonist with FDA approval for type 2 diabetes and obesity. This 20mg bulk vial provides research-grade semaglutide at ≥99% purity for extended or multi-model research protocols. HPLC and MS/MS verified per batch with third-party COA available.
Research Background
As the most extensively studied GLP-1 receptor agonist in clinical history, semaglutide provides researchers with an unparalleled reference compound for GLP-1 pathway studies. Its SUSTAIN (diabetes) and STEP (obesity) trial programs produced landmark data on glycemic control, cardiovascular outcomes, renal protection, and weight reduction. The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events in non-diabetic obese patients — establishing cardiovascular research as a major frontier for GLP-1 agonist compounds.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 20mg per vial
- Storage: −20°C, protected from light
- Molecular Weight: 4113.6 Da
- CAS Number: 910463-68-2
Certificate of Analysis
Third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
